These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23700878)

  • 1. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
    Miron L; Negură L; Peptanariu D; Marinca M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
    Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
    Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
    Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
    Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
    Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
    Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
    BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
    Colomer R; Monzo M; Tusquets I; Rifa J; Baena JM; Barnadas A; Calvo L; Carabantes F; Crespo C; Muñoz M; Llombart A; Plazaola A; Artells R; Gilabert M; Lloveras B; Alba E
    Clin Cancer Res; 2008 Feb; 14(3):811-6. PubMed ID: 18245543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
    Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
    Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
    Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
    Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
    Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
    Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
    Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
    Park IH; Lee YS; Lee KS; Kim SY; Hong SH; Jeong J; Lee H; Ro J; Nam BH
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1263-71. PubMed ID: 21442439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
    Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
    Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of aromatase inhibitors.
    Hadfield KD; Newman WG
    Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
    Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
    Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association study of aromatase gene (CYP19A1) in essential hypertension.
    Shimodaira M; Nakayama T; Sato N; Saito K; Morita A; Sato I; Takahashi T; Soma M; Izumi Y
    Int J Med Sci; 2008 Feb; 5(1):29-35. PubMed ID: 18274619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
    Liu L; Bai YX; Zhou JH; Sun XW; Sui H; Zhang WJ; Yuan HH; Xie R; Wei XL; Zhang TT; Huang P; Li YJ; Wang JX; Zhao S; Zhang QY
    Int J Mol Sci; 2013 Sep; 14(9):18973-88. PubMed ID: 24065098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDR1 C3435T polymorphism in patients with breast cancer.
    Turgut S; Yaren A; Kursunluoglu R; Turgut G
    Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of third-generation aromatase inhibitors.
    Turkistani A; Marsh S
    Expert Opin Pharmacother; 2012 Jun; 13(9):1299-307. PubMed ID: 22594760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.